These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 18464292)

  • 41. Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α.
    Fan Y; Li H; Ma X; Gao Y; Bao X; Du Q; Ma M; Liu K; Yao Y; Huang Q; Zhang Y; Zhang X
    Oncotarget; 2016 Apr; 7(14):18280-94. PubMed ID: 26943772
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma.
    Sandlund J; Oosterwijk E; Grankvist K; Oosterwijk-Wakka J; Ljungberg B; Rasmuson T
    BJU Int; 2007 Sep; 100(3):556-60. PubMed ID: 17608827
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
    Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
    J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic and predictive biomarkers in renal cell carcinoma.
    Vickers MM; Heng DY
    Target Oncol; 2010 Jun; 5(2):85-94. PubMed ID: 20582732
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clear cell papillary renal cell carcinoma-like tumors in patients with von Hippel-Lindau disease are unrelated to sporadic clear cell papillary renal cell carcinoma.
    Williamson SR; Zhang S; Eble JN; Grignon DJ; Martignoni G; Brunelli M; Wang M; Gobbo S; Baldridge LA; Cheng L
    Am J Surg Pathol; 2013 Aug; 37(8):1131-9. PubMed ID: 23648463
    [TBL] [Abstract][Full Text] [Related]  

  • 46. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
    Brauch H; Weirich G; Brieger J; Glavac D; Rödl H; Eichinger M; Feurer M; Weidt E; Puranakanitstha C; Neuhaus C; Pomer S; Brenner W; Schirmacher P; Störkel S; Rotter M; Masera A; Gugeler N; Decker HJ
    Cancer Res; 2000 Apr; 60(7):1942-8. PubMed ID: 10766184
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analyses of Potential Predictive Markers and Response to Targeted Therapy in Patients with Advanced Clear-cell Renal Cell Carcinoma.
    Song Y; Huang J; Shan L; Zhang HT
    Chin Med J (Engl); 2015 Aug; 128(15):2026-33. PubMed ID: 26228213
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic profile and immunohistochemical study of clear cell renal carcinoma: Pathological-anatomical correlation and prognosis.
    Diez-Calzadilla NA; Noguera Salvá R; Soriano Sarrió P; Martínez-Jabaloyas JM
    Cancer Treat Res Commun; 2021; 27():100374. PubMed ID: 33932757
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
    Cho D; Signoretti S; Dabora S; Regan M; Seeley A; Mariotti M; Youmans A; Polivy A; Mandato L; McDermott D; Stanbridge E; Atkins M
    Clin Genitourin Cancer; 2007 Sep; 5(6):379-85. PubMed ID: 17956710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
    Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
    J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Alteration of VHL gene in patients with metastatic renal cell carcinoma].
    Peters MV; Matveev VB; Volkova MI; Kalinin SA; Mikhaĭlenko DM
    Urologiia; 2012; (3):22-7. PubMed ID: 23074928
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mutational status of VHL gene and its clinical importance in renal clear cell carcinoma.
    Alves MR; Carneiro FC; Lavorato-Rocha AM; da Costa WH; da Cunha IW; de Cássio Zequi S; Guimaraes GC; Soares FA; Carraro DM; Rocha RM
    Virchows Arch; 2014 Sep; 465(3):321-30. PubMed ID: 25027579
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Senescence-associated protein p400 is a prognostic marker in renal cell carcinoma.
    Macher-Goeppinger S; Bermejo JL; Schirmacher P; Pahernik S; Hohenfellner M; Roth W
    Oncol Rep; 2013 Nov; 30(5):2245-53. PubMed ID: 23982490
    [TBL] [Abstract][Full Text] [Related]  

  • 54. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
    J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters.
    Kondo K; Yao M; Yoshida M; Kishida T; Shuin T; Miura T; Moriyama M; Kobayashi K; Sakai N; Kaneko S; Kawakami S; Baba M; Nakaigawa N; Nagashima Y; Nakatani Y; Hosaka M
    Genes Chromosomes Cancer; 2002 May; 34(1):58-68. PubMed ID: 11921283
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The polymorphisms in the VHL and HIF1A genes are associated with the prognosis but not the development of renal cell carcinoma.
    Qin C; Cao Q; Ju X; Wang M; Meng X; Zhu J; Yan F; Li P; Ding Q; Chen J; Gu M; Zhang W; Yin C; Zhang Z
    Ann Oncol; 2012 Apr; 23(4):981-9. PubMed ID: 21778301
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunohistochemical co-expression of PAX2 and CAIX predicts better prognosis in clear cell renal cell carcinoma after nephrectomy: A retrospective observational study.
    Shao H; Liao Y; Xiang M; Hu D; Liu S
    Cell Mol Biol (Noisy-le-grand); 2024 Jun; 70(6):129-134. PubMed ID: 38836670
    [TBL] [Abstract][Full Text] [Related]  

  • 58. von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME.
    Tedesco L; Elguero B; Pacin DG; Senin S; Pollak C; Garcia Marchiñena PA; Jurado AM; Isola M; Labanca MJ; Palazzo M; Yankilevich P; Fuertes M; Arzt E
    Cell Death Dis; 2019 Mar; 10(4):266. PubMed ID: 30890701
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
    Atkins M; Regan M; McDermott D; Mier J; Stanbridge E; Youmans A; Febbo P; Upton M; Lechpammer M; Signoretti S
    Clin Cancer Res; 2005 May; 11(10):3714-21. PubMed ID: 15897568
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review.
    Kim BJ; Kim JH; Kim HS; Zang DY
    Oncotarget; 2017 Feb; 8(8):13979-13985. PubMed ID: 28103578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.